Intermittent treatment of OFF episodes in patients with PD treated with CD/LD.
1 dose per OFF period, no more than 5 doses a day.
Nonselective MAOIs (e.g., phenelzine, tranylcypromine) due to hypertension risk. Discontinue their use at least 2 weeks prior to initiating INBRIJA.
INBRIJA is indicated for intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD) treated with carbidopa/levodopa.
Please see the Full Prescribing Information.
Our Statement on COVID-19
March 26, 2020
Since the initial outbreak of COVID-19, Acorda has been closely monitoring our supply chain for potential impact to the supply of our medicines. Acorda sources active pharmaceutical ingredient (API) for INBRIJA® (levodopa inhalation powder) from Japan and the drug product is manufactured in the United States. INBRIJA continues to be available through a dedicated specialty pharmacy network. Acorda communicates with these dedicated pharmacies on a daily basis or as frequently as needed to ensure that all eligible patients continue to have uninterrupted access to their INBRIJA. All patient support services remain active and can be offered without interruption.